keyword
MENU ▼
Read by QxMD icon Read
search

spect Pet parkinson

keyword
https://www.readbyqxmd.com/read/29222835/effective-network-of-deep-brain-stimulation-of-subthalamic-nucleus-with-bimodal-positron-emission-tomography-functional-magnetic-resonance-imaging-in-parkinson-s-disease
#1
Hui-Min Chen, Zhi-Qiang Sha, Hui-Zi Ma, Yong He, Tao Feng
AIMS: Deep brain stimulation of the subthalamic nucleus (STN-DBS) has become an effective treatment strategy for patients with Parkinson's disease. However, the biological mechanism underlying DBS treatment remains poorly understood. METHOD: In this study, we investigated how STN-DBS modulated the brain network using a bimodal positron emission tomography (PET)/functional magnetic resonance imaging (fMRI) dataset. We first performed an activation likelihood estimation meta-analysis of 13 PET/SPECT studies concerning STN-DBS effects on resting-state brain activity in Parkinson's disease...
December 8, 2017: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29165839/striatal-dopamine-in-parkinson-disease-a-meta-analysis-of-imaging-studies
#2
REVIEW
Valtteri Kaasinen, Tero Vahlberg
A meta-analysis of 142 positron emission tomography and single photon emission computed tomography studies that have investigated striatal presynaptic dopamine function in Parkinson disease (PD) was performed. Subregional estimates of striatal dopamine metabolism are presented. The aromatic L-amino-acid decarboxylase (AADC) defect appears to be consistently smaller than the dopamine transporter and vesicular monoamine transporter 2 defects, suggesting upregulation of AADC function in PD. The correlation between disease severity and dopamine loss appears linear, but the majority of longitudinal studies point to a negative exponential progression pattern of dopamine loss in PD...
December 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28990131/diagnosis-and-management-of-cognitive-and-behavioral-changes-in-dementia-with-lewy-bodies
#3
REVIEW
Babak Tousi
Proper diagnosis of dementia with Lewy bodies (DLB) in clinical practice remains suboptimal as many cases are misdiagnosed, usually as Alzheimer disease (AD) or Parkinson's disease (PD) and, in rare cases, psychosis. Therefore, it is important for patients with dementia to be thoroughly evaluated by a specialist who is familiar with current diagnostic tests and treatment options. New diagnostic criteria from the Dementia with Lewy Bodies Consortium have been developed to increase diagnostic sensitivity for DLB (Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium; McKeith et al...
October 9, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28952628/metal-complexes-for-multimodal-imaging-of-misfolded-protein-related-diseases
#4
S Lacerda, J-F Morfin, C F G C Geraldes, É Tóth
Aggregation of misfolded proteins and progressive polymerization of otherwise soluble proteins is a common hallmark of a wide range of highly debilitating and increasingly prevalent diseases, including amyotrophic lateral sclerosis, cerebral amyloid angiopathy, type II diabetes and Parkinson's, Huntington's and Alzheimer's diseases. There is a growing interest in creating imaging agents to detect such aggregates in various imaging modalities, including PET, SPECT and MRI. We present here an overview of recent efforts from the perspective of early diagnosis of amyloid diseases, with a major focus on Aβ detection and metal complexes bearing PiB units...
October 31, 2017: Dalton Transactions: An International Journal of Inorganic Chemistry
https://www.readbyqxmd.com/read/28856542/imaging-behavioural-complications-of-parkinson-s-disease
#5
Mikaeel Valli, Alexander Mihaescu, Antonio P Strafella
In addition to motor symptoms, behavioural complications are commonly found in patients with Parkinson's disease (PD). Behavioural complications, including depression, anxiety, apathy, impulse control disorder and psychosis, together have a large impact on PD patient's quality of life. Many neuroimaging studies using PET, SPECT and MRI techniques have been conducted to study the underlying neural mechanisms of PD pathogenesis and pathophysiology in relation to its behavioural complications. This review will survey these PET, SPECT and MRI studies to describe the current understanding of the neuro-chemical, functional and structural changes associated with behavioural complications in PD patients...
August 30, 2017: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/28734065/fdg-pet-dopamine-transporter-spect-and-olfaction-combining-biomarkers-in-rem-sleep-behavior-disorder
#6
Sanne K Meles, David Vadasz, Remco J Renken, Elisabeth Sittig-Wiegand, Geert Mayer, Candan Depboylu, Kathrin Reetz, Sebastiaan Overeem, Angelique Pijpers, Fransje E Reesink, Teus van Laar, Lisette Heinen, Laura K Teune, Helmut Höffken, Marcus Luster, Karl Kesper, Sofie M Adriaanse, Jan Booij, Klaus L Leenders, Wolfgang H Oertel
BACKGROUND: Idiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD-related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD-related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder. METHODS: In this cross-sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent 18 F-fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing...
October 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28554409/imaging-in-parkinson-s-disease
#7
Marios Politis, Gennaro Pagano, Flavia Niccolini
Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by the loss of nigrostriatal dopaminergic neurons and aggregation of misfolded α-synuclein in Lewy bodies. The underlying mechanisms of neurodegeneration in PD are still unknown, and there are no disease-modifying treatments to slow the neurodegenerative processes. There is an urgent need to identify biomarkers that are able to monitor disease progression and assess the development and efficacy of novel disease-modifying drugs. Over the past years, neuroimaging techniques such as magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET) have provided important advances in our understanding of PD...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/28332488/parkinson-disease
#8
REVIEW
Werner Poewe, Klaus Seppi, Caroline M Tanner, Glenda M Halliday, Patrik Brundin, Jens Volkmann, Anette-Eleonore Schrag, Anthony E Lang
Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability...
March 23, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28302035/translational-multimodality-neuroimaging
#9
Sushil Sharma
BACKGROUND: Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remains a significant challenge...
2017: Current Drug Targets
https://www.readbyqxmd.com/read/27740992/positron-emission-tomography-and-single-photon-emission-computed-tomography-in-neurology
#10
Robert S Miletich
PURPOSE OF REVIEW: Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are now available for routine clinical applications in neurology. This article discusses their diagnostic use in dementia, brain tumors, epilepsy, parkinsonism, cerebrovascular disease, and traumatic brain injury. RECENT FINDINGS: Neuromolecular imaging, also known as nuclear neurology, involves clinical imaging of both basal regional physiology (perfusion, metabolism, and transport mechanisms) and specific neurochemical physiology (currently, only the dopamine transporter)...
October 2016: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/27540431/brain-18-f-fdg-18-f-florbetaben-pet-ct-123-i-fp-cit-spect-and-cardiac-123-i-mibg-imaging-for-diagnosis-of-a-cerebral-type-of-lewy-body-disease
#11
Axel Van Der Gucht, Laurent Cleret de Langavant, Ophélie Bélissant, Corentin Rabu, Anne-Ségolène Cottereau, Eva Evangelista, Julia Chalaye, Sophie Bonnot-Lours, Gilles Fénelon, Emmanuel Itti
A 67-year-old man was referred for fluctuating neuropsychiatric symptoms, featuring depression, delirious episodes, recurrent visual hallucinations and catatonic syndrome associated with cognitive decline. No parkinsonism was found clinically even under neuroleptic treatment. (18)F-FDG PET/CT showed hypometabolism in the posterior associative cortex including the occipital cortex, suggesting Lewy body dementia, but (123)I-FP-CIT SPECT was normal and cardiac (123)I-MIBG imaging showed no signs of sympathetic denervation...
September 2016: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27432669/single-photon-emission-tomography
#12
REVIEW
Karolien Goffin, Koen van Laere
Single-photon emission computed tomography (SPECT) is a functional nuclear imaging technique that allows visualization and quantification of different in vivo physiologic and pathologic features of brain neurobiology. It has been used for many years in diagnosis of several neurologic and psychiatric disorders. In this chapter, we discuss the current state-of-the-art of SPECT imaging of brain perfusion and dopamine transporter (DAT) imaging. Brain perfusion SPECT imaging plays an important role in the localization of the seizure onset zone in patients with refractory epilepsy...
2016: Handbook of Clinical Neurology
https://www.readbyqxmd.com/read/27430452/movement-disorders
#13
REVIEW
A Jon Stoessl, Martin J Mckeown
Movement disorders can be hypokinetic (e.g., parkinsonism), hyperkinetic, or dystonic in nature and commonly arise from altered function in nuclei of the basal ganglia or their connections. As obvious structural changes are often limited, standard imaging plays less of a role than in other neurologic disorders. However, structural imaging is indicated where clinical presentation is atypical, particularly if the disorder is abrupt in onset or remains strictly unilateral. More recent advances in magnetic resonance imaging (MRI) may allow for differentiation between Parkinson's disease and atypical forms of parkinsonism...
2016: Handbook of Clinical Neurology
https://www.readbyqxmd.com/read/27407017/synthesis-and-in%C3%A2-vivo-evaluation-of-fluorine-18-and-iodine-123-pyrazolo-4-3-e-1-2-4-triazolo-1-5-c-pyrimidine-derivatives-as-pet-and-spect-radiotracers-for-mapping-a2a-receptors
#14
Christine Vala, Thomas J Morley, Xuechun Zhang, Caroline Papin, Adriana Alexandre S Tavares, H Sharon Lee, Cristian Constantinescu, Olivier Barret, Vincent M Carroll, Ronald M Baldwin, Gilles D Tamagnan, David Alagille
Imaging agents that target adenosine type 2A (A2A ) receptors play an important role in evaluating new pharmaceuticals targeting these receptors, such as those currently being developed for the treatment of movement disorders like Parkinson's disease. They are also useful for monitoring progression and treatment efficacy by providing a noninvasive tool to map changes in A2A receptor density and function in neurodegenerative diseases. We previously described the successful evaluation of two A2A -specific radiotracers in both nonhuman primates and in subsequent human clinical trials: [(123) I]MNI-420 and [(18) F]MNI-444...
September 6, 2016: ChemMedChem
https://www.readbyqxmd.com/read/27306201/-molecular-imaging-in-neurological-diseases
#15
M Reimold, C la Fougère
In neurodegeneration and in neuro-oncology, the standard imaging procedure, magnetic resonance imaging (MRI), shows limited sensitivity and specificity. Molecular imaging with specific positron-emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers allows various molecular targets and metabolic processes to be assessed and is thus a valuable adjunct to MRI. Two important examples are referred to here: amino acid transport for neuro-oncological issues, and the recently approved PET tracers for detecting amyloid depositions during the preclinical stage of Alzheimer's disease...
July 2016: Der Radiologe
https://www.readbyqxmd.com/read/27264343/functional-neuroimaging-and-clinical-features-of-drug-naive-patients-with-de-novo-parkinson-s-disease-and-probable-rbd
#16
Dario Arnaldi, Silvia Morbelli, Andrea Brugnolo, Nicola Girtler, Agnese Picco, Michela Ferrara, Jennifer Accardo, Ambra Buschiazzo, Fabrizio de Carli, Marco Pagani, Flavio Nobili
INTRODUCTION: The association between Parkinson Disease (PD) and REM sleep behavior disorder (RBD) has been related to a specific, malignant clinical phenotype. Definite RBD diagnosis requires video-polysomnography that is often unfeasible. A malignant clinical PD-RBD phenotype could be expected also in PD patients with probable RBD. Aim of this cross-sectional study was to evaluate whether a more severe neuropsychological and functional neuroimaging phenotype can be identified in PD patients with probable RBD...
August 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/27199649/metabolic-covariant-network-in-relation-to-nigrostriatal-degeneration-in-carbon-monoxide-intoxication-related-parkinsonism
#17
Chiung-Chih Chang, Jung-Lung Hsu, Wen-Neng Chang, Shu-Hua Huang, Chi-Wei Huang, Ya-Ting Chang, Nai-Ching Chen, Chun-Chung Lui, Chen-Chang Lee, Shih-Wei Hsu
Presence of parkinsonian features after carbon monoxide (CO) intoxication is well known and the severity was found to relate to the pre-synaptic dopaminergic deficits. There is no systemic study to analyse the functional network involved in CO-related Parkinsonism. Forty-five CO-related parkinsonism patients and 25 aged-matched controls completed the 3D T1-weighted imaging and (18)F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET). Voxel-based morphometry (VBM) was performed to assess the structural and functional brain differences between the patients and controls...
2016: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/27190023/in-vivo-imaging-of-neuromelanin-in-parkinson-s-disease-using-18f-av-1451-pet
#18
Allan K Hansen, Karoline Knudsen, Thea P Lillethorup, Anne M Landau, Peter Parbo, Tatyana Fedorova, Hélène Audrain, Dirk Bender, Karen Østergaard, David J Brooks, Per Borghammer
The tau tangle ligand (18)F-AV-1451 ((18)F-T807) binds to neuromelanin in the midbrain, and may therefore be a measure of the pigmented dopaminergic neuronal count in the substantia nigra. Parkinson's disease is characterized by progressive loss of dopaminergic neurons. Extrapolation of post-mortem data predicts that a ∼30% decline of nigral dopamine neurons is necessary to cause motor symptoms in Parkinson's disease. Putamen dopamine terminal loss at disease onset most likely exceeds that of the nigral cell bodies and has been estimated to be of the order of 50-70%...
July 2016: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/27182078/design-of-a-multi-pinhole-collimator-for-i-123-datscan-imaging-on-dual-headed-spect-systems-in-combination-with-a-fan-beam-collimator
#19
Michael A King, Joyeeta M Mukherjee, Arda Könik, I George Zubal, Joyoni Dey, Robert Licho
For the 2011 FDA approved Parkinson's Disease (PD) SPECT imaging agent I-123 labeled DaTscan, the volume of interest (VOI) is the interior portion of the brain. However imaging of the occipital lobe is also required with PD for calculation of the striatal binding ratio (SBR), a parameter of significance in early diagnosis, differentiation of PD from other disorders with similar clinical presentations, and monitoring progression. Thus we propose the usage of a combination of a multi-pinhole (MPH) collimator on one head of the SPECT system and a fan-beam on the other...
February 2016: IEEE Transactions on Nuclear Science
https://www.readbyqxmd.com/read/27098829/cingulate-island-sign-on-fdg-pet-is-associated-with-medial-temporal-lobe-atrophy-in-dementia-with-lewy-bodies
#20
Tomomichi Iizuka, Masashi Kameyama
OBJECTIVE: The cingulate island sign (CIS), which refers to sparing of the posterior cingulate relative to the precuneus and cuneus, has been proposed as an FDG-PET imaging feature of dementia with Lewy bodies (DLB). The sign is reportedly associated with Alzheimer's disease (AD) type neurofibrillary tangle (NFT) pathology in autopsy cases. To confirm this relationship using neuroimaging modalities in vivo, we investigated associations between CIS and the medial temporal lobe (MTL) atrophy in DLB...
July 2016: Annals of Nuclear Medicine
keyword
keyword
96258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"